Skip to main content
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
Dr. John Cush @RheumNow( View Tweet )
May 09, 2022
Depression was studied in 208 #PSA patients - Depression was found in 30%. Depression risk was higher in those with higher disease activity (DAPSA; P=.007) and functional impairment (HAQ-DI; p=-.02) https://t.co/0bZ2xPprTp https://t.co/Gdiic5iKCi
Dr. John Cush @RheumNow( View Tweet )
Apr 08, 2022
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.




  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
RheumNow Podcast square

PsA All the Way – Unmet Needs

Apr 01, 2022

Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss

Read Article
Do you discuss/screen for depression with your patients when discussing pain and fatigue? #RNL2022 @RheumNow

Dr. Rachel Tate @uptoTate( View Tweet )

Mar 20, 2022
RheumNow Podcast square

Hand OA and Heroes in Rheumatology (2.11.2022)

Feb 11, 2022

Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.

Read Article
Tofacitinib 1st JAK Inhibitor Approved for Ankylosing Spondylitis The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced.https://t.co/NczbrBXBl7 https://t.co/l93OM86qaX
Dr. John Cush @RheumNow( View Tweet )
Dec 17, 2021
RheumNow Podcast square

Indications Awaiting (12.17.21)

Dec 17, 2021

There's good news and bad news in rheumatology fellowship matching for 2022.  There's also new FDA approvals and indications, but a new serious safety warning has arisen from the CDC about the J&J COVID-19 vaccine. 

Dr. Jack Cush reviews the latest news, journal reports, regulatory

Read Article
RA.Ow02.jpg

Better assessment and management of multimorbidity

Nov 26, 2021

Appropriate assessment and management of comorbidities and multimorbidity in patients with RA is vital for overall health and well-being of the patient, as well as to encourage treatment adherence, and address social, psychological and quality of life factors. 

Read Article
brain.mri2_.jpg

Cognitive Impairment in Patients with Rheumatoid Arthritis

Nov 10, 2021

Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive

Read Article
Dementia is ⬆️in #RheumatoidArthritis says Elena Myasoedva but #RA has more DM &CV disease which ⬆️dementia. Need to separate vascular dementia from Alzheimer’s. When I trained we thought less dementia in RA -likely not true. More work is coming. 9T213 aging hub #ACR21 @RheumNow
Nov 09, 2021
#Depression is associated with a 3x increased mortality risk in patients with incident #RA. 👉🏼Results from #DANBIO 👉🏼~11000 RA pts, ~1000 starting antidepressants Abs#1659 #ACR21 @RheumNow https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK
Mrinalini Dey @DrMiniDey( View Tweet )
Nov 09, 2021
#ACR21 Ab#1036. Rheum is often the field of uncertainty. @zach_wallace_md shows uncertainty correlates w/ depression, anxiety, sickness impact across rheum diseases ⭐️Is uncertainty something to target as intervention? @Rheumnow https://t.co/v9kbk2hCqO https://t.co/50ELS3ZQp9
Nov 08, 2021
@Sineadm15 @bososhea on undiagnosed depression in axSpA. Common, and associated with worse disease activity and quality of life. Abstr#1305 #ACR21 @RheumNow https://t.co/PBH1F3XEGv
Richard Conway @RichardPAConway( View Tweet )
Nov 08, 2021
RA.Ow02.jpg

Towards better assessment and management of multimorbidity

Nov 06, 2021

Appropriate assessment and management of comorbidities and multimorbidity in patients with RA is vital for overall health and well-being of the patient, as well as to encourage treatment adherence, and address social, psychological and quality of life factors. 

Read Article
HCP #burnout coping strategies listed during 6S228 Let’s talk about mental health #ACR21 - writing, yoga, exercise, gardening, drawing& other creativity. I practice gratitude 🙏🏻 @RheumNow Burnout is real and magnified by #COVID19 pressures https://t.co/PUklM2Ci6e
Nov 06, 2021
3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower education, hx job change due to axSpA associated w/difficulties/perceived difficulties. Earlier dx/rx AND advocacy needed. Abs 0366 #ACR21 #RheumNow @RheumNow https://t.co/dlGhOymxVQ https://t.co/CWD6U1vRE0
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 06, 2021
#ACR21 Abst#0284. RA and Dementia? ⭐️1366 pts with RA, retro pop-based cohort ⭐️Risks: older age, diabetes, CVD. ⭐️Large joint swelling swelling HR 2.2 (1.2-3.9). No significance by RF/CCP/ESR/erosions/nodules ▶️CVD risks appear > RA activityhttps://t.co/2uN2lBs4tr @Rheumnow https://t.co/HEOXPosE5Z
Nov 06, 2021
If you see a patient with fatigue and arthralgias please screen for depression before you order a battery of serologies. Pain is a common feature of depression #MedEd https://t.co/0FCugZRbgI
Yousaf Ali MD @yousafali_md( View Tweet )
Oct 30, 2021
×